COMBINATION OF ANTI-CLAUDIN 18.2 / ANTI-4-1BB ANTIBODY AND A SECOND THERAPEUTIC AGENT IN CANCER TREATMENT

ID202605953APending Publication Date: 2026-07-17I MAB BIOPHARMA US LTD +1
0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
ID · ID
Patent Type
Applications
Current Assignee / Owner
I MAB BIOPHARMA US LTD
Filing Date
2024-09-27
Publication Date
2026-07-17
Patent Text Reader

Abstract

The use of combinations of bispecific and multispecific antibodies targeting both claudin 18.2 (CLDN18.2) and 4-1BB with a second therapeutic agent in the treatment of cancer is disclosed.
Need to check novelty before this filing date? Find Prior Art